drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous cellular immunotherapy consisting of patient-derived, tumor-specific T cells (TIL-like) expanded ex vivo via antigen presentation and infused intravenously to recognize leukemia neoantigens/associated antigens via TCR and mediate cytotoxic killing of malignant blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor‑reactive T cells are enriched and expanded ex vivo via antigen presentation and then infused intravenously; they use their endogenous TCRs to recognize leukemia neoantigens/leukemia‑associated antigens in an HLA‑restricted manner and mediate cytotoxic killing of malignant blasts via perforin/granzyme pathways.
drug_name
Hema-NeoTIL01
nct_id_drug_ref
NCT06559644